A glimmer of hope for older people with acute myeloid leukaemia

Mené sur 168 patients atteints d’une leucémie myéloïde aiguë récemment diagnostiquée ou récidivante ou réfractaire, cet essai de phase II évalue l’efficacité, du point de vue de la réponse globale, et la toxicité d’un traitement combinant vénétoclax et décitabine dispensée pendant 10 jours

Résumé en anglais

Acute myeloblastic leukaemia (AML) is a disease affecting older people, with an age at diagnosis between 69 and 72 years. 1 AML is a biologically heterogeneous disease that, although classified by its genetic profile, offers different responses with uniform treatments. Older patients suffer from higher toxicity and worse clinical outcomes due to pre-existing comorbidities and adverse biological characteristics of their disease, and therefore, only a small fraction of the them are treated with a curative intent, 2 obtaining 40–65% complete remission (CR) rates, at the expense of a substantial rate of early deaths. Less than 10% of patients are alive at 5 years from diagnosis. 1 , 2 Consequently, innovative strategies are required to address this unmet medical need.